ADI脂质纳米粒的制备表征及药动学研究

目的 制备并表征维生素E琥珀酸聚乙二醇酯(D-alpha-Tocopheryl polyethylene glycol 1000 succinate,TPGS)修饰载精氨酸脱亚胺酶(arginine deiminase,ADI)磺丁基-β-环糊精脂质体纳米粒(TPSG modified ADI sulfobutyl-β...

Preparation,Characterization and Pharmacokinetic Study of Arginine Deiminase Lipid Nanoparticles

  Objective  To prepare and characterize D-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified arginine deiminase (ADI) sulfobutyl-β-Cyclodextrin liposome nanoparticles (ATCL), and to investigate the pharmacokinetic characteristics of ATCL in animals.  Methods  The reverse evaporation method was used to prepare ATCL, and the particle size and Zeta potential of ATCL were measured. Thiosemicarbazone-diacetylmonooxime colorimetric method was used to measure the activity of ADI. After intravenous administration, blood was drawn at set intervals of time and the enzyme activity in the plasma was measured. Enzyme activity-time curve was drawn subsequently and Debris Assessment Software (DAS) 2.1.1 was used to analyze the pharmacokinetic characteristics.  Results  The particle size and the potential of ATCL were (216.1±13.6) nm and (?19.4±2.1) mV, respectively. The optimal temperature and optimal pH for the catalytic reaction of ADI and ATCL were the same, both being 37 ℃ and pH6.5. Results of the analysis showed that the AUC_{(0-168 h)}, MRT_{(0-168 h)}, C_max, T_max, and t_1/2 of ATCL were 3.99, 2.56, 1.58, 3.2, and 9.88 times those of free ADI, respectively. Compared with ADI, the bioavailability of ATCL increased by 298.54%.  Conclusion  ATCL prepared in the study can effectively improve the enzyme activity and bioavailability of ADI in Sprague-Dawley rats.